[go: up one dir, main page]

NI201700129A - Azabenzimidazoles y su uso como moduladores del receptor ampa. - Google Patents

Azabenzimidazoles y su uso como moduladores del receptor ampa.

Info

Publication number
NI201700129A
NI201700129A NI201700129A NI201700129A NI201700129A NI 201700129 A NI201700129 A NI 201700129A NI 201700129 A NI201700129 A NI 201700129A NI 201700129 A NI201700129 A NI 201700129A NI 201700129 A NI201700129 A NI 201700129A
Authority
NI
Nicaragua
Prior art keywords
azabenzimidazoles
receptor modulators
ampa receptor
compounds
formula
Prior art date
Application number
NI201700129A
Other languages
English (en)
Inventor
G B Berry Cynthia
Chen Gang
Loic Jourdan Fabrice
Patrick Lebold Terry
Wei LIN David
Angel Pena Piñon Miguel
Ravula Suchitra
M Savall Bradley
M Swanson Devin
Wu Dongpei
Zhang Wei
K Ameriks Michael
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NI201700129A publication Critical patent/NI201700129A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporcionan compuestos de fórmula (I), y sales farmacéuticas aceptables, N-óxidos, o solvatos de los mismos. También se proporcionan composiciones farmacéuticas que comprenden compuestos de fórmula (I) y métodos para utilizar los compuestos de fórmula (I).
NI201700129A 2015-04-29 2017-10-27 Azabenzimidazoles y su uso como moduladores del receptor ampa. NI201700129A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562154313P 2015-04-29 2015-04-29

Publications (1)

Publication Number Publication Date
NI201700129A true NI201700129A (es) 2019-05-10

Family

ID=56008859

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201700129A NI201700129A (es) 2015-04-29 2017-10-27 Azabenzimidazoles y su uso como moduladores del receptor ampa.

Country Status (39)

Country Link
US (5) US11312712B2 (es)
EP (3) EP3901153A1 (es)
JP (2) JP6800886B2 (es)
KR (2) KR102782808B1 (es)
CN (1) CN107835814B (es)
AR (1) AR104447A1 (es)
AU (2) AU2016255434C1 (es)
BR (2) BR122023023802A2 (es)
CA (1) CA2983826A1 (es)
CO (1) CO2017011017A2 (es)
CR (1) CR20170484A (es)
CY (1) CY1124059T1 (es)
DK (1) DK3288940T5 (es)
EA (1) EA033281B1 (es)
EC (1) ECSP17074645A (es)
ES (1) ES2865330T3 (es)
GT (1) GT201700231A (es)
HR (1) HRP20210403T1 (es)
HU (1) HUE053943T2 (es)
IL (1) IL254848B (es)
JO (1) JO3654B1 (es)
LT (1) LT3288940T (es)
MA (1) MA41988B1 (es)
MD (1) MD3288940T2 (es)
MX (1) MX376113B (es)
MY (1) MY194104A (es)
NI (1) NI201700129A (es)
PH (1) PH12017501816B1 (es)
PL (1) PL3288940T3 (es)
PT (1) PT3288940T (es)
RS (1) RS61688B1 (es)
SG (1) SG11201708190UA (es)
SI (1) SI3288940T1 (es)
SM (1) SMT202100222T1 (es)
TW (1) TWI706952B (es)
UA (1) UA120304C2 (es)
UY (1) UY36654A (es)
WO (1) WO2016176460A1 (es)
ZA (1) ZA201708065B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE053943T2 (hu) 2015-04-29 2021-08-30 Janssen Pharmaceutica Nv Azabenzimidazolok és ampa receptor modulátorokként való alkalmazásuk
CN107567452B (zh) * 2015-04-29 2020-07-07 詹森药业有限公司 咪唑并哌嗪和吡唑并嘧啶以及它们作为ampa受体调节剂的用途
CN118853581A (zh) 2017-06-21 2024-10-29 美商生物细胞基因治疗有限公司 嵌合抗原受体(CARs)、组合物及其使用方法
CN107383004B (zh) * 2017-07-05 2020-04-17 浙江大学 2-氨基咪唑并吡啶类衍生物及制备和应用
CN111315735B (zh) 2017-09-04 2024-03-08 C4医药公司 二氢苯并咪唑酮
EP3693360B1 (en) * 2017-10-06 2023-12-13 Takeda Pharmaceutical Company Limited Heterocyclic compounds
LT3860998T (lt) 2018-10-05 2024-06-25 Annapurna Bio Inc. Junginiai ir kompozicijos, skirti gydyti būkles, susijusias su apj receptoriaus aktyvumu
KR20210097124A (ko) * 2018-10-30 2021-08-06 리페어 세라퓨틱스 인크. 화합물, 약제 조성물, 및 화합물 제조 방법 및 atr 키나제 억제제로서의 이것들의 사용 방법
EP3924050A1 (en) 2019-02-13 2021-12-22 PTC Therapeutics, Inc. Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia
BR112021015853A2 (pt) 2019-02-13 2021-10-05 Ptc Therapeutics, Inc. Compostos de tieno[3,2-b]piridin-7-amina para o tratamento de disautonomia familiar
UA129807C2 (uk) * 2019-07-22 2025-08-06 Ріпеа Терапьютикс Інк. Похідні заміщеного 2-морфолінопіридину як інгібітори atr-кінази
US20240076285A1 (en) * 2020-12-16 2024-03-07 Shankar Venkatraman Compounds and compositions for treating conditions associated with sting activity
CN114591338B (zh) * 2022-03-31 2023-05-09 苏州欧康维视生物科技有限公司 一种Syk和VEGFR2双靶点抑制剂的制备方法及其用途
CN115304599A (zh) * 2022-09-20 2022-11-08 浙大宁波理工学院 一种3-溴-6-异丙基-1氢-哌咯[2，3-b]并吡啶及其制备方法
CN117402148A (zh) * 2023-07-26 2024-01-16 青岛大学 一种氮-氮苯并咪唑轴手性化合物及其制备方法和应用
WO2025155167A1 (ko) * 2024-01-17 2025-07-24 주식회사 엘지화학 Cbp/p300 저해제로 사용되는 신규 화합물, 및 이를 유효성분으로 포함하는 암, 염증성 장애 또는 자가면역 질환의 예방 또는 치료용 약학 조성물
WO2025155830A1 (en) 2024-01-17 2025-07-24 Rapport Therapeutics, Inc. Crystalline forms of 3-(7-chloro-1h-indazol-5-yl)-2,5-bis(trifluoromethyl)-3h-imidazo[4,5-b]pyridine and their use in the treatment of epilepsy
WO2025217330A1 (en) * 2024-04-10 2025-10-16 Terremoto Biosciences, Inc. Cysteine covalent modifiers of akt1 and uses thereof

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55167282A (en) 1979-06-12 1980-12-26 Fujisawa Pharmaceut Co Ltd Piperazine derivative or its salt and its preparation
CN1051313A (zh) 1990-11-07 1991-05-15 鞍山市振东工业尼龙厂 尼龙球磨罐及其热装工艺
GB9210400D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
TW251284B (es) * 1992-11-02 1995-07-11 Pfizer
KR970701182A (ko) 1994-02-10 1997-03-17 스피겔 알렌 제이 벤조다이아제핀 수용체 부위의 작용물질 및 길항물질로서의 5-헤테로아릴인돌 유도체(5-heteroarylindole derivatives as benzodiazepine receptor site agonists and antagonists)
US5565483A (en) 1995-06-07 1996-10-15 Bristol-Myers Squibb Company 3-substituted oxindole derivatives as potassium channel modulators
UA54403C2 (uk) 1996-10-01 2003-03-17 Н'Юросерч А/С Похідні індол-2,3-діон-3-оксиму, фармацевтична композиція, спосіб лікування розладу чи захворювання ссавців, у тому числі людини та спосіб одержання похідних індол-2,3-діон-3-оксиму
US6613777B1 (en) 1998-03-06 2003-09-02 Chen Chen CRF antagonistic pyrazolo[4,3-b]pyridines
DE19812331A1 (de) 1998-03-20 1999-09-23 Merck Patent Gmbh Piperidinderivate
EP1100504A2 (en) 1998-07-02 2001-05-23 Eisai Co., Ltd. Pharmaceutical compositions and their uses for treatment of demyelinating disorders
AU760964B2 (en) 1998-12-31 2003-05-22 Sugen, Inc. 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activityand for use in cancer chemotherapy
GB0018473D0 (en) 2000-07-27 2000-09-13 Merck Sharp & Dohme Therapeutic agents
WO2002014294A2 (en) 2000-08-11 2002-02-21 Eli Lilly And Company Heterocyclic sulfonamide derivatives and their use for potentiating glutamate receptor function
US6548576B1 (en) 2001-11-07 2003-04-15 Bourns, Inc. Epoxy formulation adapted to be used in conjunction with no-lead solder in electronic components
GT200500185A (es) 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
CA2576765C (en) * 2004-09-03 2013-05-28 Applied Research Systems Ars Holding N.V. Pyridine methylene azolidinones and use thereof phosphoinositide inhibitors
JP5209480B2 (ja) 2005-09-30 2013-06-12 グラクソ グループ リミテッド Ｍ１受容体にて活性を有する化合物および医薬におけるそれらの使用
WO2007135529A2 (en) * 2006-05-23 2007-11-29 Pfizer Products Inc. Azabenzimidazolyl compounds as mglur2 potentiators
ATE502675T1 (de) 2006-11-03 2011-04-15 Glaxo Group Ltd Verbindungen, die den ampa-rezeptor verstärken, und deren anwendung in der medizin
WO2008113795A1 (en) 2007-03-20 2008-09-25 Glaxo Group Limited Compounds which potentiate ampa receptor and uses thereof in medicine
GB0711089D0 (en) 2007-06-08 2007-07-18 Glaxo Group Ltd Compounds
GB0716292D0 (en) 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
WO2009067607A2 (en) 2007-11-20 2009-05-28 Memory Pharmaceuticals Corporation Combinations of pde4 inhibitors and antipsychotics for the treatment of psychotic disorders
JP2011506335A (ja) 2007-12-06 2011-03-03 シェーリング コーポレイション γ−セクレターゼ調節剤
TW201012803A (en) 2008-06-06 2010-04-01 Organon Nv Heterocyclic derivatives
US20110312938A1 (en) 2008-06-30 2011-12-22 Ironwood Pharmaceuticals, Inc. Pyrrolopyridine Carboxylic Acid Derivatives
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
GB0822425D0 (en) 2008-12-09 2009-01-14 Glaxo Group Ltd Compounds
GB0822981D0 (en) 2008-12-17 2009-01-21 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
WO2011056985A2 (en) 2009-11-04 2011-05-12 Gilead Sciences, Inc. Substituted heterocyclic compounds
EA201290774A1 (ru) 2010-02-11 2013-03-29 Вандербилт Юниверсити Пиразолопиридиновые, пиразолопиразиновые, пиразолопиримидиновые, пиразолотиофеновые и пиразолотиазоловые соединения как аллостерические потенциаторы mglur4, композиции и способы лечения неврологических дисфункций
WO2011156245A2 (en) * 2010-06-09 2011-12-15 Merck Sharp & Dohme Corp. Positive allosteric modulators of mglur2
WO2011163355A1 (en) 2010-06-24 2011-12-29 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds as phosphodiesterases (pdes) inhibitors
AR082618A1 (es) 2010-08-10 2012-12-19 Takeda Pharmaceutical Derivados de tiadiazina, composiciones farmaceuticas y usos
WO2012021382A1 (en) 2010-08-12 2012-02-16 Merck Sharp & Dohme Corp. Positive allosteric modulators of mglur2
WO2013064984A1 (en) 2011-10-31 2013-05-10 Xenon Pharmaceuticals Inc. Biaryl ether sulfonamides and their use as therapeutic agents
WO2013130501A1 (en) 2012-03-01 2013-09-06 The Board Of Regents Of The University Of Texas System Bivalent ampa receptor positive allosteric modulators
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
JO3225B1 (ar) * 2012-11-27 2018-03-08 Lilly Co Eli 6-((s)-1-{1-[5-(2-هيدروكسي-إيثوكسي)-بيريدين-2-يل]-1h-بيرازول-3-يل}إيثيل)-3h-1 ، 3-بنزو ثيازول-2- أون باعتباره مضاد مستقبل ampa يعتمد على tarp- جاما 8
MD20150071A2 (ro) 2013-02-19 2016-02-29 Pfizer Inc. Compuşi azabenzimidazolici ca inhibitori ai PDE4 izoenzimelor pentru tratamentul tulburărilor SNC şi altor afecţiuni
TW201609719A (zh) 2014-05-28 2016-03-16 美國禮來大藥廠 作為ＴＡＲＰ－γ８依賴性ＡＭＰＡ受體拮抗劑之６－經取代－３Ｈ－１，３－苯并噻唑－２－酮化合物
MX373154B (es) 2015-04-03 2020-04-22 Incyte Holdings Corp Compuestos heterocíclicos como inhibidores de demetilasa 1 específica de lisina (lsd1).
HUE053943T2 (hu) 2015-04-29 2021-08-30 Janssen Pharmaceutica Nv Azabenzimidazolok és ampa receptor modulátorokként való alkalmazásuk
WO2018080918A1 (en) 2016-10-26 2018-05-03 Janssen Pharmaceutica Nv 3-aryl-2h-pyrazolo[4,3-b]pyridine compounds and their use as ampa receptor modulators
KR102417483B1 (ko) 2016-10-26 2022-07-05 얀센 파마슈티카 엔.브이. 융합된 아자헤테로사이클릭 화합물 및 ampa 수용체 조절제로서의 이들의 용도
CA3039676A1 (en) 2016-10-26 2018-05-03 Janssen Pharmaceutica Nv Fused bicylic pyridine compounds and their use as ampa receptor modulators
ES2917634T3 (es) 2018-04-09 2022-07-11 Raqualia Pharma Inc Derivados de urea cíclica fusionados como antagonista de CRHR2
JP7532386B2 (ja) 2019-02-01 2024-08-13 ハンミ ファーマシューティカルズ カンパニー リミテッド イミダゾピリジン誘導体化合物及びその用途

Also Published As

Publication number Publication date
HRP20210403T1 (hr) 2021-10-29
AU2016255434C1 (en) 2021-09-23
BR112017023147A2 (pt) 2018-07-10
SI3288940T1 (sl) 2021-07-30
MX376113B (es) 2025-03-07
JP2018518462A (ja) 2018-07-12
IL254848A0 (en) 2017-12-31
MA41988B1 (fr) 2021-03-31
AU2020210231A1 (en) 2020-08-20
CR20170484A (es) 2018-02-26
US12145934B2 (en) 2024-11-19
EA033281B1 (ru) 2019-09-30
US20230110576A1 (en) 2023-04-13
MA41988A (fr) 2018-07-03
JP6800886B2 (ja) 2020-12-16
BR112017023147B1 (pt) 2024-04-30
EP3288940A1 (en) 2018-03-07
AU2020210231B2 (en) 2021-07-22
MD3288940T2 (ro) 2021-08-31
PT3288940T (pt) 2021-04-30
IL254848B (en) 2021-01-31
WO2016176460A1 (en) 2016-11-03
EP3288940B1 (en) 2021-02-24
GT201700231A (es) 2018-12-20
US12304908B2 (en) 2025-05-20
EP3901153A1 (en) 2021-10-27
HK1252249A1 (en) 2019-05-24
AU2016255434B2 (en) 2020-05-14
TW201708217A (zh) 2017-03-01
PH12017501816A1 (en) 2018-04-23
DK3288940T3 (da) 2021-05-25
PL3288940T3 (pl) 2021-07-12
CO2017011017A2 (es) 2018-03-20
SG11201708190UA (en) 2017-11-29
US20180118740A1 (en) 2018-05-03
US20230114165A1 (en) 2023-04-13
US12139485B2 (en) 2024-11-12
AR104447A1 (es) 2017-07-19
TWI706952B (zh) 2020-10-11
CN107835814B (zh) 2021-07-23
NZ774642A (en) 2024-09-27
NZ736057A (en) 2023-08-25
ZA201708065B (en) 2019-09-25
JO3654B1 (ar) 2020-08-27
EP4144736A1 (en) 2023-03-08
CN107835814A (zh) 2018-03-23
KR20170140382A (ko) 2017-12-20
AU2016255434A1 (en) 2017-10-26
US20210284641A1 (en) 2021-09-16
UY36654A (es) 2016-10-31
CA2983826A1 (en) 2016-11-03
PH12017501816B1 (en) 2023-07-19
BR122023023802A2 (pt) 2023-12-26
ECSP17074645A (es) 2018-02-28
EA201792374A1 (ru) 2018-05-31
JP7026194B2 (ja) 2022-02-25
KR102782808B1 (ko) 2025-03-14
LT3288940T (lt) 2021-05-10
UA120304C2 (uk) 2019-11-11
ES2865330T3 (es) 2021-10-15
MY194104A (en) 2022-11-11
US11312712B2 (en) 2022-04-26
MX2017013886A (es) 2018-03-12
DK3288940T5 (da) 2021-09-20
JP2021042230A (ja) 2021-03-18
HUE053943T2 (hu) 2021-08-30
CY1124059T1 (el) 2022-05-27
RS61688B1 (sr) 2021-05-31
SMT202100222T1 (it) 2021-05-07
EP3288940B9 (en) 2021-07-21
KR20240017991A (ko) 2024-02-08
US20250230157A1 (en) 2025-07-17

Similar Documents

Publication Publication Date Title
NI201700129A (es) Azabenzimidazoles y su uso como moduladores del receptor ampa.
MX2017013874A (es) Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa.
CO2019000386A2 (es) Compuestos heterocíclicos como inmunomoduladores
SV2018005794A (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
GT201700189A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
MX2018003432A (es) Compuestos heterociclicos y usos de los mismos.
CL2018003474A1 (es) Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen.
CL2017003107A1 (es) Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak
CR20170575A (es) Nuevos derivados bicíclicos, un proceso para su preparación y composiciones farmacéuticas que los continen.
UY35485A (es) Compuestos heterocíclicos y usos de los mismos
MX2015011514A (es) Compuestos de heteroarilo y sus usos.
CR20150524A (es) Compuestos de heteroarilo y sus usos
CO2019004164A2 (es) Compuestos de piridina bicíclicos fusionados y su uso como moduladores de receptores ampa
CR20160374A (es) Ciclopentanos sustituidos en 1,2 como antagonistas del receptor de orexina
MX378389B (es) Compuestos de bencimidazolona y benzotiazolona y su uso como moduladores del receptor ampa.
MX2017000183A (es) Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides.
CO2018012020A2 (es) Derivados de piridinilo, composiciones farmacéuticas y sus usos como inhibidores aoc3
CO2019004143A2 (es) Compuestos azaheterocíclicos fusionados y su uso como moduladores de los receptores ampa
ECSP16074482A (es) Ciclopentanos, tetrahidrofuranos y pirrolidinas sustituidas como antagonistas del receptor de orexina
MX369806B (es) Compuestos de indolona y su uso como moduladores del receptor ampa.
CR20140051A (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
CR20190028A (es) Compuestos heterocíclicos como inmunomoduladores
MX375725B (es) Derivados de hidroxido de bencilo, preparacion de los mismos y uso terapeutico de los mismos.